Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2− Advanced Breast Cancer by Ram Patel, John Mathews, Caroline Hamm, Swati Kulkarni, Rasna Gupta, Tarquin Opperman, John Dean Chiong, Abdullah Nasser

Subjects: Get full text

Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial by Binghe Xu, Qingyuan Zhang, Yang Luo, Zhongsheng Tong, Tao Sun, Changping Shan, Xinlan Liu, Yumin Yao, Bing Zhao, Shusen Wang, Xiaohua Zeng, Changlu Hu, Xi Yan, Xiaojia Wang, Hongyan Jia, Zhendong Chen, Fuming Qiu, Xinhong Wu, Deyong Zhang, Tong Li

“…The LEONARDA-1, a randomized, double-blind, phase III study, was conducted to evaluate the efficacy and safety of lerociclib in HR+/HER2− locally advanced or metastatic breast cancer patients, who had relapsed or progressed on prior endocrine therapy. …”
Get full text

Safety of Abemaciclib in Indian Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced and/or Metastatic Breast Cancer: A Multicenter, Nonrandomized, Open-Label, Single-Arm, Phase 4 Study by Dinesh Chandra Doval, Tanveer Maksud, Rajnish Nagarkar, Satheesh Chiradoni Thunagappa, Rakesh Taran, Saurabh Prasad, Anoop T. Manoharan, Minish Jain, Dhruv Mehta, Prabrajya Narayan Mohapatra, Sachin Gupta, Kritarth Naman Singh, Aarohan Pruthi, Rohit Arora

Get full text

Co-targeting of metabolism using dietary and pharmacologic approaches reduces breast cancer metastatic burden by Qianying Zuo, Jin Young Yoo, Erik R. Nelson, Matthew J. Sikora, Rebecca B. Riggins, Zeynep Madak-Erdogan

“…Abstract Patients with metastatic breast cancer face reduced quality of life and increased mortality rates, necessitating more effective anti-cancer strategies. …”
Get full text

Potential antiproliferative effect of isoxazolo- and thiazolo coumarin derivatives on breast cancer mediated bone and lung metastases by Ballazhi Lulzime, Popovski Emil, Jashari Ahmed, Imeri Faik, Ibrahimi Ibrahim, Mikhova Bozhana, Mladenovska Kristina

“…The study highlights the current progress in the development of coumarin scaffolds for drug discovery as novel anticancer agents in metastatic breast cancer. Eight compounds, combining the coumarin core and five membered heterocycles (isoxazoles and thiazoles) in hydrazinyldiene- -chroman-2,4-diones, were characterized in terms of a potential antiproliferative effect on bone (SCP1833) and lung (SCP4175) metastatic breast cancer cell lines using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay. …”
Get full text

Association of Structural Maintenance of Chromosome-1A Phosphorylation with Progression of Breast Cancer by Sushma Yadav, Claudia M. Kowolik, Daniel Schmolze, Yuan Yuan, Min Lin, Arthur D. Riggs, David A. Horne

“…Immunohistochemical (IHC) staining was conducted using previously validated phospho-SMC1A antibodies on a histological section and tissue microarray (TMA) comprising samples from primary, invasive, and metastatic breast cancer and normal breast tissues. Our results revealed that p-SMC1A staining intensity was lower in normal breast tissues compared to invasive or metastatic breast cancer tissues (<i>p</i> < 0.001). …”
Get full text

Evaluation of the a-amylase enzyme, Carbohydrate Antigen CA-15.3 ( C.A 15.3),and some biochemical variables in the blood serum of breast cancer patients by Nagham abd, Ebtehal Sabri Mohammed, Amer Fadel Dawood

“…The tumor marker (C.A 15.3) is one of the most reliable markers for monitoring metastatic breast cancer. The results obtained from this study indicated that (C.A 15.3) values were high in women with breast cancer in all stages of the disease, and the values were very high especially in the last two stages of the disease. …”
Get full text

Isolated Gastrointestinal Metastasis of Breast Carcinoma: A Case Report by M. A. Titi, A. Anabtawi, A. D. Newland

“…Although more common causes for gastrointestinal symptoms should be excluded, however, a high index of suspicion of metastatic breast cancer is needed when such patients develop gastrointestinal symptoms.…”
Get full text

Diffuse Spontaneous Laryngeal Hemorrhage with Trastuzumab by Lauren Klute, Matthew Solverson, Christopher M. Bingcang, Jayme R. Dowdall

“…We present a case of hemoptysis in a young female patient undergoing treatment for metastatic breast cancer with trastuzumab emtansine. Though previously associated with diffuse spontaneous hemorrhage of the gingiva, there have not been reports of laryngeal hemorrhage with trastuzumab emtansine treatment. …”
Get full text

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer by Sara M Tolaney, Tianyu Li, Edward T Richardson, Judith Agudo, Elizabeth A Mittendorf, Beth Overmoyer, Eric P Winer, Adrienne G Waks, Tanya E Keenan, Nabihah Tayob, Gerburg M Wulf, Victoria Attaya, Leilani Anderson, Ian E Krop, Eliezer M Van Allen

“…Eligible patients had HER2-positive, metastatic breast cancer previously treated with taxane, trastuzumab, and pertuzumab, and were T-DM1-naïve. …”
Get full text

Trastuzumab Resistance: Role for Notch Signaling by Kinnari Mehta, Clodia Osipo

“…However, resistance to trastuzumab remains a major concern, most notably in women with metastatic breast cancer. Numerous mechanisms that include overexpression of alternate receptor tyrosine kinases and/or loss of critical tumor suppressors have been proposed in the last several years to elucidate trastuzumab resistance. …”
Get full text

Maternal Mortality: 10 Year Experience of a Tertiary Center in Turkey by Erdem Fadiloglu, Canan Unal, Atakan Tanacan, Serpil Ocal, Banu Kilicaslan, Seda Banu Akinci, Arzu Topeli, M. Sinan Beksac

“…Maternal mortality causes were cardiopulmonary failure secondary to veno-occlusive disease, septic shock secondary to osteosarcoma, pulmonary thromboembolism secondary to metastatic breast cancer, septic shock secondary to cholecystitis, and postpartum hemorrhage secondary to Niemann–Pick disease. …”
Get full text

Changes in Cytokines of the Bone Microenvironment during Breast Cancer Metastasis by Donna M. Sosnoski, Venkatesh Krishnan, William J. Kraemer, Courtenay Dunn-Lewis, Andrea M. Mastro

“…In this study, we examined levels of MCP-1, IL-6, KC, MIP-2, VEGF, MIG, and eotaxin in femurs of athymic nude mice inoculated via intracardiac injection with MDA-MB-231GFP human metastatic breast cancer cells, MDA-MB-231BRMS1GFP, a metastasis suppressed variant, or PBS. …”
Get full text

A Criterion-based Approach for the Systematic and Transparent Extrapolation of Clinical Trial Survival Data by Gabriel Tremblay, Patrick Haines, Andrew Briggs

“…The techniques are then applied to a metastatic breast cancer (MBC) example. **Methods:** A criterion-based guide was devised to allow the accurate extrapolation and justification of survival estimates in a MBC study comparing eribulin (Halaven) monotherapy with treatment of their (patient’s) physician’s choice (TPC). …”
Get full text

Understanding metastasis mixed-treatment responses through genomic analyses by Susana Garcia-Recio, Paola Zagami, Brooke M. Felsheim, Amy Wheless, Kerry Thomas, Renato Trimarchi, Lisa A. Carey, Charles M. Perou

“…Abstract Early-stage and metastatic breast cancers (MBC) can exhibit genomic heterogeneity, even within the same individual. …”
Get full text

Herbal Extract SH003 Suppresses Tumor Growth and Metastasis of MDA-MB-231 Breast Cancer Cells by Inhibiting STAT3-IL-6 Signaling by Youn Kyung Choi, Sung-Gook Cho, Sang-Mi Woo, Yee Jin Yun, Sunju Park, Yong Cheol Shin, Seong-Gyu Ko

“…Therefore, we conclude that SH003 suppresses highly metastatic breast cancer growth and metastasis by inhibiting STAT3-IL-6 signaling path.…”
Get full text

Everolimus Implicated in Case of Severe Gastrointestinal Hemorrhage by Paul Gonzales, Seth Klusewitz, Johanna Marowske, John Gancayco, Michael B. Osswald, Robert Setlik

“…Our case demonstrates recurrent episodes of gastrointestinal bleeding in a 60-year-old woman being treated with Everolimus for progressive metastatic breast cancer. On endoscopy, bleeding was secondary to erosive gastritis. …”
Get full text

Real-world clinical multi-omics analyses reveal bifurcation of ER-independent and ER-dependent drug resistance to CDK4/6 inhibitors by Zhengyan Kan, Ji Wen, Vinicius Bonato, Jennifer Webster, Wenjing Yang, Vladimir Ivanov, Kimberly Hyunjung Kim, Whijae Roh, Chaoting Liu, Xinmeng Jasmine Mu, Jennifer Lapira-Miller, Jon Oyer, Todd VanArsdale, Paul A. Rejto, Jadwiga Bienkowska

“…Abstract To better understand drug resistance mechanisms to CDK4/6 inhibitors and inform precision medicine, we analyze real-world multi-omics data from 400 HR+/HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors plus endocrine therapies, including 200 pre-treatment and 227 post-progression samples. …”
Get full text

Omega-3 fatty acids: molecular weapons against chemoresistance in breast cancer by Vittoria Marchio, Giuseppina Augimeri, Catia Morelli, Adele Vivacqua, Cinzia Giordano, Stefania Catalano, Diego Sisci, Ines Barone, Daniela Bonofiglio

“…However, triple-negative breast cancer (TNBC) and metastatic breast cancer disease are primarily treated with chemotherapy, which improves disease-free and overall survival, but does not offer a curative solution for these aggressive forms of breast cancer. …”
Get full text

Human Immune System Increases Breast Cancer-Induced Osteoblastic Bone Growth in a Humanized Mouse Model without Affecting Normal Bone by Tiina E. Kähkönen, Mari I. Suominen, Jenni H. E. Mäki-Jouppila, Jussi M. Halleen, Azusa Tanaka, Michael Seiler, Jenni Bernoulli

“…This model can be used for evaluating the efficacy of combination treatments of IO therapies with immune-stimulatory compounds or therapeutic approaches on bone metastatic breast cancer.…”
Get full text